We have located links that may give you full text access.
JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome.
Surgical Neurology 1986 March
Out of 936 primary intracranial meningiomas, 94.3% were histologically benign (grade I), 4.7% atypical (grade II), and 1.0% anaplastic (grade III); one recurrence was sarcomatous (grade IV). Meningiomas with histologic anaplasia (grades II-IV) occurred in 12% of the men, but only 4% of the women. Only 26% of atypical or anaplastic meningiomas appeared completely innocent on a computed tomography scan. Angiograms, usually showing a meningeal feeding artery, suggested meningioma when computed tomography scans did not. At 5 years after complete removal, the recurrence rate was only 3% (21% at 25 years) for benign meningiomas, but 38% for atypical ones, and 78% for anaplastic ones. The median times to recurrence were 7.5, 2.4, and 3.5 years, respectively. In spite of postoperative radiotherapy, four of five anaplastic meningiomas recurred.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
The Effect of Albumin Administration in Critically Ill Patients: A Retrospective Single-Center Analysis.Critical Care Medicine 2024 Februrary 8
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app